Navigation Links
Tumor target suggests personalized treatment for melanoma
Date:6/15/2010

Identification of a key player in a signaling pathway involved in the development of melanoma the deadliest form of skin cancer may offer hope for new targeted melanoma therapies.

Ann Richmond, Ph.D., and colleagues at Vanderbilt-Ingram Cancer Center report that a signaling molecule, known as IKKβ, is essential for melanoma tumor development in a mouse model of the disease. The results, published June 7 in the Journal of Clinical Investigation, also point to ways of targeting therapies that inhibit IKKβ toward the patients most likely to benefit from them based on their genetic profile.

Melanoma is the deadliest form of skin cancer and incredibly difficult to treat successfully once the tumor has spread beyond the skin.

Prior studies have shown that the NF-κB signaling pathway centered on the protein NF-κB, which regulates gene expression is abnormally activated in tumor cells; the pathway is turned "on" constantly, even at times it should be turned "off." This activation often results from abnormal activation of another enzyme in the pathway, IKKβ.

Just how NF-κB contributes to tumor progression has been unclear. And with drugs that inhibit this pathway entering clinical trials, a clearer picture of its function in tumor progression is needed.

To better understand the role of this pathway in particular, of IKKβ's role Richmond's lab developed a mouse model that mimics the genetic alterations involved in melanoma development in humans.

Jinming Yang, Ph.D., a staff scientist in Richmond's lab, led the effort to generate these mice, which lack the tumor suppressor INK4a/ARF (commonly lost in melanomas) and have the Ras/Raf pathway activated (which is activated in about 70 percent of melanoma lesions).

The researchers then added the ability to "turn off" IKKβ only in melanocytes, the pigment-producing skin cells in which melanomas initiate, simply by treating the mice with an antibiotic.

Mice with normal IKKβ activity developed "loads and loads of melanoma tumors all over their bodieson the tail, the ear, and anywhere melanocytes are," said Richmond, an Ingram Professor of Cancer Biology at Vanderbilt University Medical Center and a senior career research scientist with the Department of Veterans Affairs.

But mice in which IKKβ was "turned off" developed no melanoma tumors.

They also found that treating mice with normal IKKβ activity with small molecule inhibitors of the enzyme could inhibit the growth of melanoma lesions.

"This shows for the first time that you have to have IKKβ for Ras-induced melanoma, suggesting that there's a way to specifically target melanoma lesions," she said.

However, the experiments identified an important caveat: blocking IKKβ only seemed to protect against melanoma formation when another tumor suppressor, p53, is expressed.

Since mutations that disrupt p53 are sometimes found in melanomas, this suggests that therapies targeting IKKβ or the NF-κB pathway in general would need to be limited to tumors with normal p53.

Richmond cautions, "With NF-κB inhibitors entering clinical trials at this time, it is imperative that these data be taken into consideration for patient selection or evaluation of response in these trials."

Richmond is collaborating with Vanderbilt-Ingram Cancer Center investigators Mark Kelley, M.D., and Jeffrey Sosman, M.D., to identify, in human tumor samples, which tumors would respond to targeted inhibitors of the Ras/Raf and NF-κB pathways.

Such information could aid in diagnosis and "be used to deliver personalized medicine" to melanoma patients in the future, she said.

"We're passionate about (IKKβ inhibitors) possibly going forward, maybe not as a single agent, but in combination (treatments). As we are able to better predict which patients will respond to which drugs, there's real hope there."


'/>"/>

Contact: Dagny Stuart
dagny.stuart@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. Taking aim at metastatic lung tumors
2. Solid tumor modeling focus of workshops
3. Drug that restricts blood supply to prostate tumors delays disease progression
4. Delay in surgery not likely to worsen tumors in men with low-risk prostate cancer
5. FDA approves first human neural stem cell clinical trial to treat brain tumors
6. HPV-positive tumor status indicates better survival in patients with oropharyngeal cancer
7. Detecting tumors faster
8. Drug that helps metastatic colon cancer of no benefit in less advanced tumors
9. Bone drug suppresses wandering tumor cells in breast cancer patients
10. Study: Prostate cancer patients weight linked to tumor size
11. Size of Prostate Tumor Linked to Patients Weight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... According to ... In an industry filled with chemical-laden beauty products, one company is going against the ... for you: Mad Hippie. The rising star in the green space is proud to ...
(Date:5/26/2016)... Lake MN (PRWEB) , ... May 26, 2016 , ... ... Stance Angle chair , furniture that may support women during pregnancy. Potential benefits ... legs and feet, improved rest and comfort and healthier levels of sitting and standing. ...
(Date:5/25/2016)... (PRWEB) , ... May 26, 2016 , ... The United ... treatment of androgenetic alopecia in both men and women. To date, the company is ... with FDA clearance for any adult who suffers with androgenetic alopecia. , “This ...
(Date:5/25/2016)... ... May 25, 2016 , ... “We ... Managing Partner at HealthScape Advisors. “Brad brings significant experience advising healthcare provider clients ... system accelerates with the implementation of MACRA, we believe that continuing to add ...
(Date:5/25/2016)... Kansas City, MO (PRWEB) , ... May 25, 2016 , ... ... professional, collegiate, and amateur athletics, The National Center for Drug Free Sport (Drug Free ... Drug Free Sport”. This conference, to be held July 12 – 13 in Kansas ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
(Date:5/25/2016)... 2016 According to market research ... and Demand Forecast to 2022 - Industry Insights by ... published by P&S Market Research, the global insulin delivery ... and it is expected to grow at a CAGR ... pump segment is expected to witness the fastest growth ...
(Date:5/25/2016)... Texas , May 25, 2016 ... the issuance to it by the US Patent ... The company,s technology includes proprietary processes for electronic ... for health and wellness programs, HIPAA compliance and ... "Our technology ...
Breaking Medicine Technology: